Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LXR Biotech. -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (135)	1/7/1999 9:23:00 AM
From: BRAVEHEART	Read Replies (1) \| Respond to of 154

Hi Gang, Here is some background on LXR. This certainly does not cover the R&D end and the potential it includes. Today's announcement is suggestive of that potential. In particular the following statement relative to one of LXR's programs. "''SARPs regulate fundamental processes in the life/death cycle of cells and thereby have great potential as therapeutics,'' commented Paul J. Hastings, President and CEO of LXR. ''We are pleased that a company of the stature of Rhone-Poulenc Rorer has recognized the potential of SARPs. This collaboration is one of several that LXR plans to establish for the development of SARP technology for a number of diseases,'' added Mr. Hastings." Message 7141454 BEST WISHES LONE WOLF